Sentences with phrase «obtaining approval for»

However, the Developer undertook a substantial step towards obtaining approval for the division of the Owner's land, including spending significant amounts of money.

It is best to engage community members in a multistep process for choosing, refining, and obtaining approval for measures and tools.

Overstock relayed concerns about the difficulties it faces in obtaining approval for tZERO's trading system.

Government scientists routinely encounter difficulty in obtaining approval for official press releases that highlight research into the causes and consequences of global warming.

Knowing what the options are will help increase the credit score quickly and improve the chances of obtaining approval for additional credit products in the future.

Obtaining approval for your patient's treatment for spinal muscular atrophy (SMA) often requires your practice or facility to complete several steps, including conducting a thorough Benefit Investigation to determine if an authorization and / or medical exception is needed prior to treatment approval.

Former England international David Beckham is on the cusp of obtaining approval for the Major League Soccer expansion club in Miami, league commissioner Don Garber has revealed.

Perth - based contractor and surveyor OTOC has obtained approval for an $ 8.1 million debt facility from the Commonwealth Bank of Australia, on top of an $ 8.2 million facility it was awarded from the CBA last year.

Amarin's partner in the Middle East and North Africa, or MENA region, in the first quarter of 2018 obtained approval for Vascepa in Lebanon.

Talk of rebellion over executive compensation reached a crescendo in the UK on Thursday after Weir Group plc failed to obtain approval for their three - year binding policy, and FTSE 100 issuers Shire plc and CRH -LSB-...]

He also informed about their plans to obtain approvals for listing BIT's shares on OTCQX, under the Alternative Reporting Standards.

For instance, a journalist observed that even though many doubted the sincerity of the former National Security Adviser, Sambo Dasuki when he sought and obtained approval for postponement of 2015 general election to enable the military to degrade Boko Haram and ensure maximum security of voters, all known terrorists» camps were destroyed before the emergence of new government on May 29; Sambisa Forest was stormed by «Special «M» forces» and about 300 kidnapped women and children were freed; 22 terrorist occupied towns in three states were recovered; and Boko Haram could not disrupt the elections.

Then parents must be contacted to obtain approval for the waiver of their child.

There is not a mechanism in our rules for an individual to obtain approval for a class as clock hours.

The debtor must meet certain requirements to obtain approval for this to happen.

Both the borrower and the car must meet certain requirements to obtain approval for a bad credit car loan from My Auto Loan, but these minimum requirements are less stringent than for a traditional auto loan.

Your CDs are purchased in the brokerage account after funds are received and we obtain your approval for the purchases.

A. For people with limited, poor, or no credit, it may be difficult to obtain approval for a traditional credit card.

This is often a trick that people use after they have obtained approval for their loan and have continued to repay the installments for up to 6 months, proving that they are reliable.

But the staff would need to obtain approval for the study first.

Often, a person who can not obtain approval for a traditional credit card can receive a secured credit card.

The Borrower plans to obtain approval for the development of ap...

A member of our pharmacy team will contact your vet to obtain the approval for your pet's medication by telephone or fax.

Foreign developers who plan to distribute their game in China will now need to work with a Chinese publisher (or set up a JV) so that they can localize the game, obtain approval for the game, market the game and operate the game in China.

If the answer is yes then it won't be hard for the Chinese publisher to obtain approval for your game.

In addition, if there is subsurface material encountered that contains asbestos containing material (ACM), there may be requirements to prepare and obtain approval for an Asbestos Abatement Work Plan.

In the area of merger control, Brian regularly represents parties seeking to obtain approval for complex transactions before either the European Commission or national competition authorities.

Recently, he was a member of a team that successfully obtained approval for a wood burning electric power generating plant in eastern Connecticut.

Unbeknownst to the lawyer, the woman had conspired with the mortgage company's representative to falsify her income to obtain approval for the loan.

You don't need to wonder when or how you can obtain approval for your insurance application.

Although there are many seniors who can still easily obtain approval for life insurance, there are others who may not be able to do so due to various health related conditions.

Verified use of the software, validated contract compliance, obtained approvals for SOX purposes, processed purchase orders, updated asset management system records (Maximo) and prepared invoices for payment.

• Welcomed patients and families and inquired into their purpose of visit • Assisted patients in understanding various medical procedures and how to handle in - home care • Provided assistance in filling out first information forms and ensured that all forms were properly processed and filed • Contacted insurance agencies to obtain approvals for procedures and provided feedback to the office • Performed patient follow up duties by contacting patients to remind them of their appointments

Develop effective treatment plans and obtains approval for services from referring physician...

Prepared materials submittal schedules, submission and obtained approval for all materials lists.

Developer Joe Cassidy, president of Joe Cassidy Construction in San Francisco, effusively praises the role an animated video played in helping him find investors and financing and obtain approvals for 555 Fourth St., a 330 - unit condominium building now rising in San Francisco's South - of - Market district.

Following an MLS posting for the home, priced at $ 419,000, a buyer obtained approval for a mortgage and it sold for $ 409,000.

Not exact matches

Important factors that could cause actual results to differ materially from those reflected in such forward - looking statements and that should be considered in evaluating our outlook include, but are not limited to, the following: 1) our ability to continue to grow our business and execute our growth strategy, including the timing, execution, and profitability of new and maturing programs; 2) our ability to perform our obligations under our new and maturing commercial, business aircraft, and military development programs, and the related recurring production; 3) our ability to accurately estimate and manage performance, cost, and revenue under our contracts, including our ability to achieve certain cost reductions with respect to the B787 program; 4) margin pressures and the potential for additional forward losses on new and maturing programs; 5) our ability to accommodate, and the cost of accommodating, announced increases in the build rates of certain aircraft; 6) the effect on aircraft demand and build rates of changing customer preferences for business aircraft, including the effect of global economic conditions on the business aircraft market and expanding conflicts or political unrest in the Middle East or Asia; 7) customer cancellations or deferrals as a result of global economic uncertainty or otherwise; 8) the effect of economic conditions in the industries and markets in which we operate in the U.S. and globally and any changes therein, including fluctuations in foreign currency exchange rates; 9) the success and timely execution of key milestones such as the receipt of necessary regulatory approvals, including our ability to obtain in a timely fashion any required regulatory or other third party approvals for the consummation of our announced acquisition of Asco, and customer adherence to their announced schedules; 10) our ability to successfully negotiate, or re-negotiate, future pricing under our supply agreements with Boeing and our other customers; 11) our ability to enter into profitable supply arrangements with additional customers; 12) the ability of all parties to satisfy their performance requirements under existing supply contracts with our two major customers, Boeing and Airbus, and other customers, and the risk of nonpayment by such customers; 13) any adverse impact on Boeing's and Airbus» production of aircraft resulting from cancellations, deferrals, or reduced orders by their customers or from labor disputes, domestic or international hostilities, or acts of terrorism; 14) any adverse impact on the demand for air travel or our operations from the outbreak of diseases or epidemic or pandemic outbreaks; 15) our ability to avoid or recover from cyber-based or other security attacks, information technology failures, or other disruptions; 16) returns on pension plan assets and the impact of future discount rate changes on pension obligations; 17) our ability to borrow additional funds or refinance debt, including our ability to obtain the debt to finance the purchase price for our announced acquisition of Asco on favorable terms or at all; 18) competition from commercial aerospace original equipment manufacturers and other aerostructures suppliers; 19) the effect of governmental laws, such as U.S. export control laws and U.S. and foreign anti-bribery laws such as the Foreign Corrupt Practices Act and the United Kingdom Bribery Act, and environmental laws and agency regulations, both in the U.S. and abroad; 20) the effect of changes in tax law, such as the effect of The Tax Cuts and Jobs Act (the «TCJA») that was enacted on December 22, 2017, and changes to the interpretations of or guidance related thereto, and the Company's ability to accurately calculate and estimate the effect of such changes; 21) any reduction in our credit ratings; 22) our dependence on our suppliers, as well as the cost and availability of raw materials and purchased components; 23) our ability to recruit and retain a critical mass of highly - skilled employees and our relationships with the unions representing many of our employees; 24) spending by the U.S. and other governments on defense; 25) the possibility that our cash flows and our credit facility may not be adequate for our additional capital needs or for payment of interest on, and principal of, our indebtedness; 26) our exposure under our revolving credit facility to higher interest payments should interest rates increase substantially; 27) the effectiveness of any interest rate hedging programs; 28) the effectiveness of our internal control over financial reporting; 29) the outcome or impact of ongoing or future litigation, claims, and regulatory actions; 30) exposure to potential product liability and warranty claims; 31) our ability to effectively assess, manage and integrate acquisitions that we pursue, including our ability to successfully integrate the Asco business and generate synergies and other cost savings; 32) our ability to consummate our announced acquisition of Asco in a timely matter while avoiding any unexpected costs, charges, expenses, adverse changes to business relationships and other business disruptions for ourselves and Asco as a result of the acquisition; 33) our ability to continue selling certain receivables through our supplier financing program; 34) the risks of doing business internationally, including fluctuations in foreign current exchange rates, impositions of tariffs or embargoes, compliance with foreign laws, and domestic and foreign government policies; and 35) our ability to complete the proposed accelerated stock repurchase plan, among other things.

Granting credit approval depends on the willingness of the creditor to lend money in the current economy and that same lender's assessment of the ability and willingness of the borrower to return the money or pay for the goods obtained — plus interest — in a timely fashion.

Such factors include, among others, general business, economic, competitive, political and social uncertainties; the actual results of current and future exploration activities; the actual results of reclamation activities; conclusions of economic evaluations; meeting various expected cost estimates; changes in project parameters and / or economic assessments as plans continue to be refined; future prices of metals; possible variations of mineral grade or recovery rates; the risk that actual costs may exceed estimated costs; failure of plant, equipment or processes to operate as anticipated; accidents, labour disputes and other risks of the mining industry; political instability; delays in obtaining governmental approvals or financing or in the completion of development or construction activities, as well as those factors discussed in the section entitled «Risk Factors» in the Company's Annual Information Form for the year ended December 31, 2017 dated March 15, 2018.

Last year, Chinese pharmaceuticals obtained U.S. Food and Drug Administration approvals for 38 generic drugs, up from 22 such approvals in 2016.

Factors which could cause actual results to differ materially from these forward - looking statements include such factors as the Company's ability to accomplish its business initiatives, obtain regulatory approval and protect its intellectual property; significant fluctuations in marketing expenses and ability to achieve or grow revenue, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission.

Actual results and the timing of events could differ materially from those anticipated in the forward - looking statements due to these risks and uncertainties as well as other factors, which include, without limitation: the uncertain timing of, and risks relating to, the executive search process; risks related to the potential failure of eptinezumab to demonstrate safety and efficacy in clinical testing; Alder's ability to conduct clinical trials and studies of eptinezumab sufficient to achieve a positive completion; the availability of data at the expected times; the clinical, therapeutic and commercial value of eptinezumab; risks and uncertainties related to regulatory application, review and approval processes and Alder's compliance with applicable legal and regulatory requirements; risks and uncertainties relating to the manufacture of eptinezumab; Alder's ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; the uncertain timing and level of expenses associated with Alder's development and commercialization activities; the sufficiency of Alder's capital and other resources; market competition; changes in economic and business conditions; and other factors discussed under the caption «Risk Factors» in Alder's Annual Report on Form 10 - K for the fiscal year ended December 31, 2017, which was filed with the Securities and Exchange Commission (SEC) on February 26, 2018, and is available on the SEC's website at www.sec.gov.

Such risks and uncertainties include, but are not limited to: our ability to achieve our financial, strategic and operational plans or initiatives; our ability to predict and manage medical costs and price effectively and develop and maintain good relationships with physicians, hospitals and other health care providers; the impact of modifications to our operations and processes; our ability to identify potential strategic acquisitions or transactions and realize the expected benefits of such transactions, including with respect to the Merger; the substantial level of government regulation over our business and the potential effects of new laws or regulations or changes in existing laws or regulations; the outcome of litigation, regulatory audits, investigations, actions and / or guaranty fund assessments; uncertainties surrounding participation in government - sponsored programs such as Medicare; the effectiveness and security of our information technology and other business systems; unfavorable industry, economic or political conditions, including foreign currency movements; acts of war, terrorism, natural disasters or pandemics; our ability to obtain shareholder or regulatory approvals required for the Merger or the requirement to accept conditions that could reduce the anticipated benefits of the Merger as a condition to obtaining regulatory approvals; a longer time than anticipated to consummate the proposed Merger; problems regarding the successful integration of the businesses of Express Scripts and Cigna; unexpected costs regarding the proposed Merger; diversion of management's attention from ongoing business operations and opportunities during the pendency of the Merger; potential litigation associated with the proposed Merger; the ability to retain key personnel; the availability of financing, including relating to the proposed Merger; effects on the businesses as a result of uncertainty surrounding the proposed Merger; as well as more specific risks and uncertainties discussed in our most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.cigna.com as well as on Express Scripts» most recent report on Form 10 - K and subsequent reports on Forms 10 - Q and 8 - K available on the Investor Relations section of www.express-scripts.com.

«My apologies for not obtaining approval from the [Deputy Attorney General] earlier on.

Documents obtained exclusively by theBreaker, under the freedom of information law, show that Deputy Minister Richard Fyfe gave approval Oct. 2, 2017 for the Court Services Branch to hold its second annual leadership conference at B.C.'s biggest casino.

This is a significant positive for the company, as it allows for closer collaboration with the FDA and has the potential to shorten the clinical timeline to obtain regulatory approval.

In the event of termination of the Merger Agreement under certain circumstances principally related to a failure to obtain required regulatory approvals, the Merger Agreement provides for Facebook to pay WhatsApp a fee of $ 1 billion in cash and to issue to WhatsApp a number of shares of Facebook's Class A common stock equal to $ 1 billion based on the average closing price of the ten trading days preceding such termination date.

Actual results may vary materially from those expressed or implied by forward - looking statements based on a number of factors, including, without limitation: (1) risks related to the consummation of the Merger, including the risks that (a) the Merger may not be consummated within the anticipated time period, or at all, (b) the parties may fail to obtain shareholder approval of the Merger Agreement, (c) the parties may fail to secure the termination or expiration of any waiting period applicable under the HSR Act, (d) other conditions to the consummation of the Merger under the Merger Agreement may not be satisfied, (e) all or part of Arby's financing may not become available, and (f) the significant limitations on remedies contained in the Merger Agreement may limit or entirely prevent BWW from specifically enforcing Arby's obligations under the Merger Agreement or recovering damages for any breach by Arby's; (2) the effects that any termination of the Merger Agreement may have on BWW or its business, including the risks that (a) BWW's stock price may decline significantly if the Merger is not completed, (b) the Merger Agreement may be terminated in circumstances requiring BWW to pay Arby's a termination fee of $ 74 million, or (c) the circumstances of the termination, including the possible imposition of a 12 - month tail period during which the termination fee could be payable upon certain subsequent transactions, may have a chilling effect on alternatives to the Merger; (3) the effects that the announcement or pendency of the Merger may have on BWW and its business, including the risks that as a result (a) BWW's business, operating results or stock price may suffer, (b) BWW's current plans and operations may be disrupted, (c) BWW's ability to retain or recruit key employees may be adversely affected, (d) BWW's business relationships (including, customers, franchisees and suppliers) may be adversely affected, or (e) BWW's management's or employees» attention may be diverted from other important matters; (4) the effect of limitations that the Merger Agreement places on BWW's ability to operate its business, return capital to shareholders or engage in alternative transactions; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings, including any such proceedings related to the Merger and instituted against BWW and others; (6) the risk that the Merger and related transactions may involve unexpected costs, liabilities or delays; (7) other economic, business, competitive, legal, regulatory, and / or tax factors; and (8) other factors described under the heading «Risk Factors» in Part I, Item 1A of BWW's Annual Report on Form 10 - K for the fiscal year ended December 25, 2016, as updated or supplemented by subsequent reports that BWW has filed or files with the SEC.

To obtain lender approval for a «cosigner release,» borrowers must often meet certain underwriting criteria.